V.i. Technologies, Inc.

Other

Pentose Pharmaceuticals, Inc.

Cyclis Pharmaceuticals, Inc.

Edward I Budowsky

Samuel K Ackerman

Andrei A Purmal

Clark M Edson

Martin D Williams

Alexander E Gavrilov

Arman D Pivasyan

Methods and compositions for selectively inactivating viruses in biological compositions, including contacting the composition with an organic solvent and an ethyleneimine oligomer inactivating agent, are disclosed.

Methods and compositions for inactivating viruses

Methods and compositions for the selective modification of nucleic acids

The present invention provides methods for treating rhinoviral infections in a subject in need of such treatment, by the administration of 2&prime;-5&prime; oligoadenylates or the analogs thereof. Pharmaceutical formulations comprising 2&prime;-5&prime; oligoadenylates and analogs thereof are also provided.

Method of treating rhinoviral infections

This invention provides means and methods of inactivating viruses and other organisms in cell-containing or biopolymer-containing compositions without significant alteration of proteins or other biopolymers by contacting such compositions with selective ethyleneimine oligomer inactivating agents, such as the trimer or tetramer.

Methods for the selective modification of viral nucleic acids

The means and methods of inactivating viruses and other organisms in cell-containing or biopolymer-containing compositions comprising contacting such compositions with selective ethyleneimine oligomer inactivating agents are disclosed. The means and methods of this invention selectively modify functional nucleic acids in a cell-containing or biopolymer-containing composition using selective ethyleneimine oligomer inactivating agents, such as the trimer or tetramer without significant alteration of proteins or other biopolymers.

Methods and compositions for the selective modification of viral nucleic

Methods and compositions for selectively modifying nucleic acid molecules in biological compositions, including contacting the composition with an inactivating agent having the formula: ##STR1## where each of R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.6, R.sub.7, and R.sub.8 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.6, R.sub.7, and R.sub.8 cannot all be H; R.sub.5 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; X is a pharmaceutically acceptable counter-ion; and n is an integer between 1 and 10, inclusive are disclosed.

A method for treating diseases and symptoms caused by papillomaviruses is presented. The method comprises administering an effective amount of one or more 2',5'-oligoadenylates consisting of the structure: ##STR1## wherein R.sub.2 is PO.sub.4.sup.2- and R.sub.3 is OH, R.sub.2 and R.sub.3 are OH; and n=1 or n=2.

Method of treating papillomavirus using 2',5'-oligoadenylate

The present invention provides methods for treating herpes infections in a subject in need of such treatment, by the administration of 2'-5' oligoadenylate-2',3'-cyclophosphate compounds. Pharmaceutical formulations comprising 2'-5' oligoadenylate-2',3'-cyclophosphate and compounds thereof are also provided.

Method of treating herpes infections with

The present invention concerns a method for inactivating a virus for use in e.g. a vaccine, by treating the virus with an ethyleneimine at a pH of less than 7.0, and methods of treatment with the inactivated virus.

Growing community of inventors

Brookline, MA, United States of America

Edward I Budowsky